BMY vs DGX: fair value comparison
Bristol-Myers Squibb Company and Quest Diagnostics Incorporated · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BMY currently sits closer to the top of our discount ranking.
| BMY | DGX | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $66.58 | $242.76 |
| 12-month range | $46.02–$65.47 | $173.79–$233.01 |
| Sector rank | #101 of 113 Healthcare | #105 of 113 Healthcare |
| Quality grade | C | C |
| Momentum grade | B | B |
| Leverage | High | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · DGX fair value analysis